Plasmonic Gold Chip for Multiplexed Detection of Ovarian Cancer Biomarker in Urine

doi:10.1007/s40242-022-2117-7

Chemical Research in Chinese Universities ›› 2022, Vol. 38 ›› Issue (4): 935-940.doi: 10.1007/s40242-022-2117-7

• Articles • Previous Articles Next Articles

Plasmonic Gold Chip for Multiplexed Detection of Ovarian Cancer Biomarker in Urine

CHEN Minwen¹, LIAO Tao¹, ZENG Linsheng³, ZENG Zhongyi³, YANG Qinglai^1,2, WANG Guoxin¹

1. WWHS Biotech. Inc., Shenzhen 518000, P. R. China;
2. Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, School of Preclinical Medicine, Hengyang Medical School, University of South China, Hengyang 421001, P. R. China;
3. Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, P. R. China

Received:2022-03-30 Revised:2022-05-11 Online:2022-08-01 Published:2022-07-01
Contact: YANG Qinglai;WANG Guoxin E-mail:qingyu513@usc.edu.cn; wanggx@wwhsbio.com
Supported by:
This work was supported by the Research and Development Projects in Key Areas of Guangdong Province, China(No.2020B1111160003), the Science and Technology Planning Project of Shenzhen City, China (No.JSGG20191231141403880), the National Natural Science Foundation of China(No.81801749), the Key Research and Development Program of Hunan Province, China(No.2022SK2053), the Science and Technology Innovation Program of Hunan Province "Huxiang Young Talents Plan", China (No.2021RC3106), and the Science and Technology Foundation of Shenzhen City, China(No.JCYJ20190812164009243).

Abstract

Abstract: Human epididymal protein 4(HE4), carbohydrate antigen 125 (CA125) and osteopontin(OPN) are three key biomarkers in detecting ovarian cancer. To explore the diagnosis value of combined detection of these three biomarkers for ovarian cancer, we developed a multiplexed assay on a plasmonic gold(pGOLD) platform for measuring HE4, CA125 and OPN in urine. The receiver operator characteristic(ROC) curve was drawn, and the diagnosis values of each biomarker alone or in combination for ovarian cancer were evaluated. In the analysis to distinguish ovarian cancer from other gynecological cancers, ovarian cysts and healthy people, the sensitivities of HE4, CA125 and OPN were 72.55%, 52.82% and 68.63%, the specificity values were 95.06%, 87.65% and 90.12%, while the areas under the curve(AUC) were 0.85, 0.75 and 0.77, respectively. The sensitivity and specificity for combination detection of the three markers were 90.20% and 80.25%. The detection methods of HE4, CA125 and OPN based on plasma fluorescence enhanced chip showed good analytic and diagnostic performance, and provided a non-invasive method for the diagnosis of ovarian cancer.

Key words: Plasmonic gold chip, Urine, Ovarian cancer, Multiplexed detection

CHEN Minwen, LIAO Tao, ZENG Linsheng, ZENG Zhongyi, YANG Qinglai, WANG Guoxin. Plasmonic Gold Chip for Multiplexed Detection of Ovarian Cancer Biomarker in Urine[J]. Chemical Research in Chinese Universities, 2022, 38(4): 935-940.

References

[1] Siegel R. L., Miller K. D., Jemal A., CA Cancer J. Clin., 2019, 69, 7
[2] Jayson G. C., Kohn E. C., Kitchener H. C., Ledermann J. A., The Lancet, 2014, 384, 1376
[3] Earle C. C., Schrag D., Neville B. A., Yabroff K. R., Topor M., Fahey A., Trimble E. L., Bodurka D. C., Bristow R. E., Carney M., Warren J. L., JNCI:Journal of the National Cancer Institute, 2006, 98, 172
[4] Paulsen T., Kjærheim K., KÆRN J., Tretli S., Tropé C., International Journal of Gynecologic Cancer, 2006, 16, 11
[5] Carney M. E., Lancaster J. M., Ford C., Tsodikov A., Wiggins C. L., Gynecol Oncol., 2002, 84, 36
[6] Pei C., Liu C., Wang Y., Cheng D., Li R., Shu W., Zhang C., Hu W., Jin A., Yang Y., Wan J., Angew. Chem. Int. Ed., 2020, 59, 10831
[7] Su H., Li X., Huang L., Cao J., Zhang M., Vedarethinam V., Di W., Hu Z., Qian K., Adv. Mater., 2021, 33, 2007978
[8] Samarah L. Z., Vertes A., VIEW, 2020, 1, 20200063
[9] Tabakman S. M., Lau L., Robinson J. T., Price J., Sherlock S. P., Wang H., Zhang B., Chen Z., Tangsombatvisit S., Jarrell J. A., Utz P. J., Dai H., Nature Communications, 2011, 2, 466
[10] Zhang B., Yang J., Zou Y., Gong M., Chen H., Hong G., Antaris A. L., Li X., Liu C.-L., Chen C., Dai H., Chemical Science, 2014, 5, 4070
[11] Koh B., Li X., Zhang B., Yuan B., Lin Y., Antaris A. L., Wan H., Gong M., Yang J., Zhang X., Liang Y., Dai H., Small, 2016, 12, 457
[12] Goodman M. T., Howe H. L., Tung K. H., Hotes J., Miller B. A., Coughlin S. S., Chen V. W., Cancer, 2003, 97, 2676
[13] Pearl M. L., Zhao Q., Yang J., Dong H., Tulley S., Zhang Q., Golightly M., Zucker S., Chen W.-T., Gynecol Oncol., 2014, 134, 581
[14] Hacker N. F., Rao A., Best Practice& Research Clinical Obstetrics& Gynaecology, 2017, 41, 71
[15] Davidson B., TropéC. G., Womens Health, 2014, 10, 519
[16] Aust S., Pils D., Wien Med Wochenschr, 2014, 164, 479
[17] Rustin G. J. S., Vergote I., Eisenhauer E., Pujade-Lauraine E., Quinn M., Thigpen T., du Bois A., Kristensen G., Jakobsen A., Sagae S., Greven K., Parmar M., Friedlander M., Cervantes A., Vermorken J., International Journal of Gynecologic Cancer, 2011, 21, 419
[18] Clauss A., Lilja H., LundwallÅ., Biochem. J., 2002, 368, 233
[19] Trudel D., Têtu B., Grégoire J., Plante M., Renaud M.-C., Bachvarov D., Douville P., Bairati I., Gynecol Oncol., 2012, 127, 511
[20] Drapkin R., von Horsten H. H., Lin Y., Mok S. C., Crum C. P., Welch W. R., Hecht J. L., Cancer Res., 2005, 65, 2162
[21] Yuan C., Li R., Yan S., Kong B., Clinical Chemistry and Laboratory Medicine (CCLM), 2018, 56, 1026
[22] Steffensen K. D., Waldstrøm M., Brandslund I., Petzold M., Jakobsen A., International Journal of Gynecologic Cancer, 2012, 22, 1474
[23] Rainczuk A., Condina M., Pelzing M., Dolman S., Rao J., Fairweather N., Jobling T., Stephens A. N., J. Proteome. Res., 2013, 12, 4074
[24] Rosen D. G., Wang L., Atkinson J. N., Yu Y., Lu K. H., Diamandis E. P., Hellstrom I., Mok S. C., Liu J., Bast R. C., Gynecol Oncol., 2005, 99, 267
[25] Rustin G. J. S., Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology, 2003, 21, 187s
[26] Brakora K. A., Lee H., Yusuf R., Sullivan L., Harris A., Colella T., Seiden M. V., Gynecol Oncol., 2004, 93, 361
[27] Guan G. F., Journal of Medical Forum,2009, 30, 9
[28] Han H.-F., Yen H.-C., Wu H.-C., Tan H.-Y., Xu W., Jiang H.-S., Tsai P.-J., Qian K., Wu Y.-C., Chen C.-C., ACS Applied Materials& Interfaces, 2021, 13, 57036
[29] Xu W., Wang L., Zhang R., Sun X., Huang L., Su H., Wei X., Chen C.-C., Lou J., Dai H., Qian K., Nature Communications, 2020, 11, 1654
[30] Zhang R., Le B., Xu W., Guo K., Sun X., Su H., Huang L., Huang J., Shen T., Liao T., Liang Y., Zhang J. X. J., Dai H., Qian K., Small Methods, 2019, 3, 1800474

Plasmonic Gold Chip for Multiplexed Detection of Ovarian Cancer Biomarker in Urine

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 9

Recommended Articles

Metrics

Comments

[1]	LIU Qianyu, DU Zhenwu, ZHU He, ZHAO Tianyu, PAN Ying. Comprehensive Analysis of Differential Gene Expression Profile via RNA Sequencing in the Human Ovarian Cancer SKOV3 Cells Treated with Simvastatin [J]. Chemical Research in Chinese Universities, 2022, 38(2): 632-638.
[2]	SUN Dan, LIU Xiangyuan, XU Shuping, TIAN Yu, XU Weiqing and TAO Yanchun. Quantitative Determination of Urine Glucose: Combination of Laminar Flow in Microfluidic Chip with SERS Probe Technique [J]. Chemical Research in Chinese Universities, 2018, 34(6): 899-904.
[3]	ZHANG Hai-tao, LI Zhuo, ZHANG Jun-bo, ZHANG Yang, YE Jian-nong, CHU Qing-cui, ZHANG Mei-jiang. Simultaneous Determination of Catecholamines and Related Metabolites by Capillary Electrophoresis with Amperometric Detection [J]. Chemical Research in Chinese Universities, 2013, 29(5): 850-853.
[4]	WANG Li-ying, LI Hong, YANG Shi-jie. Taurine Inhibits Myocardial Fibrosis via PKC-ERK1/2 Signaling Pathways [J]. Chemical Research in Chinese Universities, 2012, 28(1): 84-90.
[5]	WASEEM Amir*, YAQOOB Mohammad, NABI Abdul, MURTAZA Ghulam and HUSSAIN Izhar. Flow-injection Spectrophotometric Determination of Uric Acid in Urine via Prussian Blue Reaction [J]. Chemical Research in Chinese Universities, 2011, 27(6): 929-933.
[6]	ZHANG Hong-guo, XIAO Ying-hong, YANG Long-fei, SU Wei-heng, GUAN Xin-gang, .... Altered Taurine Release in Hypothalamus of Aquaporin-4 Knockout Mice [J]. Chemical Research in Chinese Universities, 2010, 26(3): 406-408.
[7]	ZHANG Zhi-li, ZHOU Shou-xin, WANG Xiao-wei, WANG Hong-tao, CHEN Yan-li, LIU Jun-yi. Tetra-n-butylammonium Hydroxide: an Efficient Catalyst for N-Alkylation of Pyrimidines and Purines [J]. Chemical Research in Chinese Universities, 2006, 22(4): 451-454.
[8]	LIN Li, QIU Pei-hong, XIE Xia-feng, CAO Xu-ni, JIN Li-tong. Determination of 6-Mercaptopurine in Rat Blood by Microdialysis Coupled with High Performance Liquid Chromatography on a Functionalized Multi-wall Carbon Nanotubes Modified Electrode [J]. Chemical Research in Chinese Universities, 2005, 21(2): 141-144.
[9]	HE Zhi-ke, LIU Xing-lian, LUO Qing-yao, YU Xi-mao, ZENG Yun'e. Chemiluminescence Determination of 6-Mercaptopurine in Pharmaceuticals [J]. Chemical Research in Chinese Universities, 1995, 11(3): 266-270.